Cargando…

Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65

Leber congenital amaurosis is a group of inherited retinal dystrophies that cause severe sight impairment in childhood; RPE65-deficiency causes impaired rod photoreceptor function from birth and progressive impairment of cone photoreceptor function associated with retinal degeneration. In animal mod...

Descripción completa

Detalles Bibliográficos
Autores principales: Georgiadis, A, Duran, Y, Ribeiro, J, Abelleira-Hervas, L, Robbie, S J, Sünkel-Laing, B, Fourali, S, Gonzalez-Cordero, A, Cristante, E, Michaelides, M, Bainbridge, J W B, Smith, A J, Ali, R R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5143366/
https://www.ncbi.nlm.nih.gov/pubmed/27653967
http://dx.doi.org/10.1038/gt.2016.66
_version_ 1782472925652189184
author Georgiadis, A
Duran, Y
Ribeiro, J
Abelleira-Hervas, L
Robbie, S J
Sünkel-Laing, B
Fourali, S
Gonzalez-Cordero, A
Cristante, E
Michaelides, M
Bainbridge, J W B
Smith, A J
Ali, R R
author_facet Georgiadis, A
Duran, Y
Ribeiro, J
Abelleira-Hervas, L
Robbie, S J
Sünkel-Laing, B
Fourali, S
Gonzalez-Cordero, A
Cristante, E
Michaelides, M
Bainbridge, J W B
Smith, A J
Ali, R R
author_sort Georgiadis, A
collection PubMed
description Leber congenital amaurosis is a group of inherited retinal dystrophies that cause severe sight impairment in childhood; RPE65-deficiency causes impaired rod photoreceptor function from birth and progressive impairment of cone photoreceptor function associated with retinal degeneration. In animal models of RPE65 deficiency, subretinal injection of recombinant adeno-associated virus (AAV) 2/2 vectors carrying RPE65 cDNA improves rod photoreceptor function, and intervention at an early stage of disease provides sustained benefit by protecting cone photoreceptors against retinal degeneration. In affected humans, administration of these vectors has resulted to date in relatively modest improvements in photoreceptor function, even when retinal degeneration is comparatively mild, and the duration of benefit is limited by progressive retinal degeneration. We conclude that the demand for RPE65 in humans is not fully met by current vectors, and predict that a more powerful vector will provide more durable benefit. With this aim we have modified the original AAV2/2 vector to generate AAV2/5-OPTIRPE65. The new configuration consists of an AAV vector serotype 5 carrying an optimized hRPE65 promoter and a codon-optimized hRPE65 gene. In mice, AAV2/5-OPTIRPE65 is at least 300-fold more potent than our original AAV2/2 vector.
format Online
Article
Text
id pubmed-5143366
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-51433662016-12-23 Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65 Georgiadis, A Duran, Y Ribeiro, J Abelleira-Hervas, L Robbie, S J Sünkel-Laing, B Fourali, S Gonzalez-Cordero, A Cristante, E Michaelides, M Bainbridge, J W B Smith, A J Ali, R R Gene Ther Short Communication Leber congenital amaurosis is a group of inherited retinal dystrophies that cause severe sight impairment in childhood; RPE65-deficiency causes impaired rod photoreceptor function from birth and progressive impairment of cone photoreceptor function associated with retinal degeneration. In animal models of RPE65 deficiency, subretinal injection of recombinant adeno-associated virus (AAV) 2/2 vectors carrying RPE65 cDNA improves rod photoreceptor function, and intervention at an early stage of disease provides sustained benefit by protecting cone photoreceptors against retinal degeneration. In affected humans, administration of these vectors has resulted to date in relatively modest improvements in photoreceptor function, even when retinal degeneration is comparatively mild, and the duration of benefit is limited by progressive retinal degeneration. We conclude that the demand for RPE65 in humans is not fully met by current vectors, and predict that a more powerful vector will provide more durable benefit. With this aim we have modified the original AAV2/2 vector to generate AAV2/5-OPTIRPE65. The new configuration consists of an AAV vector serotype 5 carrying an optimized hRPE65 promoter and a codon-optimized hRPE65 gene. In mice, AAV2/5-OPTIRPE65 is at least 300-fold more potent than our original AAV2/2 vector. Nature Publishing Group 2016-12 2016-09-22 /pmc/articles/PMC5143366/ /pubmed/27653967 http://dx.doi.org/10.1038/gt.2016.66 Text en Copyright © 2016 The Author(s) https://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/
spellingShingle Short Communication
Georgiadis, A
Duran, Y
Ribeiro, J
Abelleira-Hervas, L
Robbie, S J
Sünkel-Laing, B
Fourali, S
Gonzalez-Cordero, A
Cristante, E
Michaelides, M
Bainbridge, J W B
Smith, A J
Ali, R R
Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65
title Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65
title_full Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65
title_fullStr Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65
title_full_unstemmed Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65
title_short Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65
title_sort development of an optimized aav2/5 gene therapy vector for leber congenital amaurosis owing to defects in rpe65
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5143366/
https://www.ncbi.nlm.nih.gov/pubmed/27653967
http://dx.doi.org/10.1038/gt.2016.66
work_keys_str_mv AT georgiadisa developmentofanoptimizedaav25genetherapyvectorforlebercongenitalamaurosisowingtodefectsinrpe65
AT durany developmentofanoptimizedaav25genetherapyvectorforlebercongenitalamaurosisowingtodefectsinrpe65
AT ribeiroj developmentofanoptimizedaav25genetherapyvectorforlebercongenitalamaurosisowingtodefectsinrpe65
AT abelleirahervasl developmentofanoptimizedaav25genetherapyvectorforlebercongenitalamaurosisowingtodefectsinrpe65
AT robbiesj developmentofanoptimizedaav25genetherapyvectorforlebercongenitalamaurosisowingtodefectsinrpe65
AT sunkellaingb developmentofanoptimizedaav25genetherapyvectorforlebercongenitalamaurosisowingtodefectsinrpe65
AT fouralis developmentofanoptimizedaav25genetherapyvectorforlebercongenitalamaurosisowingtodefectsinrpe65
AT gonzalezcorderoa developmentofanoptimizedaav25genetherapyvectorforlebercongenitalamaurosisowingtodefectsinrpe65
AT cristantee developmentofanoptimizedaav25genetherapyvectorforlebercongenitalamaurosisowingtodefectsinrpe65
AT michaelidesm developmentofanoptimizedaav25genetherapyvectorforlebercongenitalamaurosisowingtodefectsinrpe65
AT bainbridgejwb developmentofanoptimizedaav25genetherapyvectorforlebercongenitalamaurosisowingtodefectsinrpe65
AT smithaj developmentofanoptimizedaav25genetherapyvectorforlebercongenitalamaurosisowingtodefectsinrpe65
AT alirr developmentofanoptimizedaav25genetherapyvectorforlebercongenitalamaurosisowingtodefectsinrpe65